Copyright
©The Author(s) 2022.
World J Hepatol. Jul 27, 2022; 14(7): 1470-1479
Published online Jul 27, 2022. doi: 10.4254/wjh.v14.i7.1470
Published online Jul 27, 2022. doi: 10.4254/wjh.v14.i7.1470
Table 2 Outcomes by group (n [per patient-yr])
Vaccinated (n = 33.8 patient-yr) | Unvaccinated (n = 82.1 patient-yr) | P value | |
COVID-19 cases | |||
Total | 4 (11.8%)/3 (8.9%)1 | 24 (29.2%) | 0.035/0.0131 |
Mild | 1 (3.0%) | 7 (8.5%) | 0.260 |
Moderate | 3 (8.9%)/2 (5.9%)1 | 5 (6.1%) | 0.431/0.6661 |
Severe | 0 | 12 (14.6%) | 0.012 |
Death | |||
Overall | 1 (3.0%) | 14 (17.1%) | 0.001 |
Associated with COVID-19 | 0 | 10 (12.2%) | 0.012 |
Liver-related | 1 (3.0%) | 4 (4.9%) | 0.135 |
Non-COVID-19 complications (cases) | |||
Liver decompensation | 4 (11.9%) | 21 (25.6%) | 0.077 |
Bleeding esophageal varices | 2 (5.9%) | 8 (9.7%) | 0.394 |
Myocardial infarction | 0 | 1 (1.2%) | 0.707 |
Pulmonary embolism | 0 | 1 (1.2%) | 0.707 |
Stroke | 0 | 0 | - |
Transient ischemic attack | 1 (3.0%) | 0 | 0.293 |
Abdominal thrombosis | 0 | 0 | - |
- Citation: Ivashkin V, Ismailova A, Dmitrieva K, Maslennikov R, Zharkova M, Aliev S, Bakhitov V, Marcinkevich V. Efficacy and safety of COVID-19 vaccination in patients with cirrhosis. World J Hepatol 2022; 14(7): 1470-1479
- URL: https://www.wjgnet.com/1948-5182/full/v14/i7/1470.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i7.1470